Skip to content
Back to all use casesCommercial

HTA Market Access Pro

The problem

Problem statement

Preparing Health Technology Assessment (HTA) submissions for market access requires pulling together clinical, economic, and comparator evidence from many sources, a process that's slow and hard to standardize across markets. Build an HTA market access tool that organizes and structures the evidence needed for HTA dossiers, helping market access teams prepare stronger submissions faster.

One-pager

HTA Insight Navigator

Market Access Intelligence Prototype

AI-powered multi-country HTA evidence intelligence for market access planning

01 PROTOTYPE OVERVIEW

Prototype Overview

Prototype Name: HTA Insight Navigator
Initiative: Agilisium Forward Deployment Experts (FDX)
Category: Market Access & HEOR

HTA Insight Navigator is an AI-powered prototype that enables pharmaceutical market access teams to rapidly assess publicly available clinical evidence and Health Technology Assessment (HTA) considerations across multiple countries. By consolidating evidence sources, HTA frameworks, and market access insights into a single interface, the solution helps teams accelerate evidence discovery, compare country-specific requirements, and support early market access strategy development.

02 WHAT THE PROTOTYPE IS ABOUT

What the Prototype Is About

Preparing market access strategies requires teams to review clinical evidence, understand country-specific HTA methodologies, and navigate multiple public information sources such as PubMed, ClinicalTrials.gov, NICE, and G-BA. This process is often manual, fragmented, and time-consuming.

HTA Insight Navigator provides a unified evidence intelligence workspace where users can select a drug, indication, and line of therapy to generate structured HTA insights, compare market access considerations across countries, and quickly access relevant evidence sources.

03 KEY FEATURES

Key Features

Multi-Country HTA Comparison – Compare HTA frameworks, evidence expectations, reimbursement considerations, and market access risks across Germany, the UK, and the US.

Evidence Intelligence – Generate direct evidence search links to PubMed and ClinicalTrials.gov for the selected drug and indication.

Therapy-Specific Context – Display indication-specific HTA considerations, including oncology, rare diseases, and other therapeutic areas.

Market Access Insights – Summarize key evidence expectations, comparator considerations, pricing implications, and potential market access risks.

Evidence Navigation – Provide quick access to publicly available scientific literature and clinical trial registries from a single interface.

04 EXPECTED BUSINESS IMPACT

Expected Business Impact

HTA Insight Navigator helps market access and HEOR teams reduce manual evidence discovery efforts while improving consistency in early access planning. The prototype is expected to:

Accelerate evidence discovery and literature review

Improve visibility into country-specific HTA requirements

Support consistent cross-country market access assessments

Enable faster identification of evidence gaps

Strengthen collaboration across Market Access, Medical Affairs, and HEOR teams

05 INTENDED AUDIENCE

Intended Audience

Global Market Access Teams

HEOR & Evidence Generation Teams

Pricing & Reimbursement Specialists

Medical Affairs

Commercial Strategy & Launch Excellence Teams

Market Access Consultants

06 FDX CONTEXT

FDX Context

HTA Insight Navigator demonstrates Agilisium's FDX approach by combining AI with market access domain expertise to streamline evidence intelligence workflows. The prototype showcases how AI-assisted evidence discovery can support informed, transparent, and efficient market access planning while leveraging publicly available scientific and HTA resources.